DiaMedica Therapeutics, Inc.
DiaMedica-Logo
Navigate DiaMedica Therapeutics, Inc.
Home
About Us
Company Overview
Leadership Team
Board of Directors
Clinical Advisory Boards
Science
Our Science
Pipeline
Diseases We Target
Overview
IgA Nephropathy
African Americans - Hypertensive with CKD
Acute Ischemic Stroke
Investors & Media
Investors Home
Press Releases
Events & Presentations
Nasdaq Stock Information
Analyst Coverage
Financial Reports
Governance
Investor Resources
Careers
Contact
Home
News
Press Releases
Press Releases
All News
By Year:
2020
2019
2018
2017
2016
Dec 17, 2019
DiaMedica Therapeutics Announces First Patient Dosed in REDUX Phase II Clinical Trial of DM199 for the Treatment of Chronic Kidney Disease
Nov 13, 2019
DiaMedica Therapeutics Announces Third Quarter 2019 Financial Results and Provides Business Update
Nov 6, 2019
DiaMedica Therapeutics to Report Third Quarter 2019 Financials and Provide a Business Update November 14, 2019
Nov 5, 2019
DiaMedica Therapeutics to Participate in 10th Annual Craig-Hallum Alpha Select Conference
Oct 14, 2019
DiaMedica Therapeutics Announces Clearance to Initiate Phase II Clinical Trial of DM199 for Chronic Kidney Disease
Sep 6, 2019
DiaMedica Therapeutics to Present at Lake Street’s 3rd Annual Best Ideas Growth (BIG3) Conference on September 12, 2019
Sep 3, 2019
DiaMedica Therapeutics to Present at the 2019 Dougherty & Co. Institutional Investor Conference
Aug 13, 2019
DiaMedica Therapeutics Announces Second Quarter 2019 Financial Results and Provides Business Update
Aug 12, 2019
DiaMedica Therapeutics to Present at the 2019 Intellisight Investor Conference on August 14, 2019
Aug 8, 2019
DiaMedica Therapeutics to Report Second Quarter 2019 Financials and Provide a Business Update August 13, 2019
1
2
3
Next »